Home > The Company

The Company

Aries Pharmaceuticals Inc. (Aries) is a wholly owned subsidiary of Aries Pharmaceuticals, Ltd., which is a wholly owned Subsidiary of Cosmo Pharmaceuticals, NV, a specialty pharmaceutical and medical device company focused on developing and commercializing best in class products in endoscopy and to treat gastrointestinal diseases. Aries is in charge of the distribution in the US of the Cosmo products.

Aries’ first product to reach the market, Eleview™, is an injectable composition intended for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early stage cancers or other mucosal lesions prior to excision.

In addition to Eleview™, Aries will distribute, upon approval, three further endoscopy/gastrointestinal focused products:

  • Rifamycin SV MMX, with recently announced positive phase III data in travelers’ diarrhea and phase II trials underway for IBS-D and uncomplicated diverticulitis
  • LuMeBlue®, with recently announced phase III data in the increase of adenoma detection rate in colonoscopies compared to standard of care.
  • Remimazolam, in-licensed by Cosmo Pharmaceuticals, NV from PAION UK, a subsidiary of PAION AG and currently in Phase III development for procedural sedation with recently announced positive Phase III data in patients undergoing colonoscopy.The completion of the 2nd pivotal study in Bronchoscopy patients is expected to be completed in Q2 2017.

Aries is building the infrastructure to commercialize these products starting with the launch of Eleview™in the first half of 2017.